NCT03822455View on ClinicalTrials.gov

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

March 11, 2020

Study Completion Date

July 10, 2021

Conditions
Cystic Fibrosis
Interventions
DRUG

OligoG DPI

OligoG Dry Powder for Inhalation

Trial Locations (1)

Unknown

John Hunter Hospital, Newcastle

Sponsors

Lead Sponsor

AlgiPharma AS
All Listed Sponsors
lead

AlgiPharma AS

INDUSTRY

NCT03822455 - A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis | Biotech Hunter | Biotech Hunter